Equities analysts predict that Albireo Pharma Inc (NASDAQ:ALBO) will report earnings of ($0.97) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Albireo Pharma’s earnings, with estimates ranging from ($1.08) to ($0.68). Albireo Pharma reported earnings per share of ($0.73) during the same quarter last year, which would suggest a negative year-over-year growth rate of 32.9%. The company is scheduled to issue its next earnings report before the market opens on Tuesday, November 13th.
According to Zacks, analysts expect that Albireo Pharma will report full year earnings of ($3.39) per share for the current fiscal year, with EPS estimates ranging from ($3.70) to ($2.75). For the next fiscal year, analysts forecast that the business will post earnings of ($3.95) per share, with EPS estimates ranging from ($6.06) to ($2.13). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that follow Albireo Pharma.
Albireo Pharma (NASDAQ:ALBO) last released its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.98) by ($0.24). The firm had revenue of $0.73 million for the quarter, compared to analysts’ expectations of $2.00 million.
Shares of ALBO stock traded down $2.25 during trading on Friday, hitting $25.84. 33,307 shares of the stock traded hands, compared to its average volume of 66,310. The firm has a market cap of $333.36 million, a PE ratio of -8.20 and a beta of 1.74. Albireo Pharma has a 52-week low of $21.25 and a 52-week high of $39.87.
In other news, insider Ronald Harold Wilfred Cooper bought 788 shares of the business’s stock in a transaction on Tuesday, August 14th. The shares were bought at an average price of $31.85 per share, with a total value of $25,097.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.60% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Federated Investors Inc. PA raised its position in Albireo Pharma by 89.1% in the second quarter. Federated Investors Inc. PA now owns 586,146 shares of the biopharmaceutical company’s stock valued at $20,808,000 after purchasing an additional 276,221 shares during the period. BlackRock Inc. raised its position in shares of Albireo Pharma by 11.4% in the 3rd quarter. BlackRock Inc. now owns 584,177 shares of the biopharmaceutical company’s stock valued at $19,255,000 after acquiring an additional 59,901 shares during the period. Chicago Capital LLC raised its position in shares of Albireo Pharma by 18.9% in the 3rd quarter. Chicago Capital LLC now owns 160,248 shares of the biopharmaceutical company’s stock valued at $5,282,000 after acquiring an additional 25,500 shares during the period. Millennium Management LLC raised its position in shares of Albireo Pharma by 234.0% in the 1st quarter. Millennium Management LLC now owns 155,611 shares of the biopharmaceutical company’s stock valued at $5,068,000 after acquiring an additional 109,017 shares during the period. Finally, Heartland Advisors Inc. raised its position in shares of Albireo Pharma by 36.9% in the 2nd quarter. Heartland Advisors Inc. now owns 125,000 shares of the biopharmaceutical company’s stock valued at $4,438,000 after acquiring an additional 33,677 shares during the period. 63.44% of the stock is currently owned by institutional investors.
About Albireo Pharma
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Featured Story: Technical Analysis of Stocks, How Can It Help
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.